SAN DIEGO--(BUSINESS WIRE)--Zogenix, Inc. (“Zogenix”), a private, specialty pharmaceutical company, today announced that it has filed a registration statement with the Securities and Exchange Commission ("SEC") relating to the proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. The shares of common stock to be sold in this offering are proposed to be sold by Zogenix, Inc.
Banc of America Securities LLC is the sole book-running manager for the offering. Leerink Swann, Thomas Weisel Partners LLC and Susquehanna Financial Group, LLLP are co-lead managers. This offering will be made only by means of a prospectus. Once available, a copy of the preliminary prospectus for this offering may be obtained from Banc of America Securities LLC, Capital Markets (Prospectus Fulfillment) by e-mail to email@example.com or by mail to Banc of America Securities LLC, Capital Markets Operations, 100 West 33rd Street, 3rd Floor, New York, NY 10001.
A registration statement relating to these securities has been filed with the SEC, but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
Zogenix, Inc., with offices in Emeryville and San Diego, CA, is a private, specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. The company's lead product candidate, sumatriptan DosePro™ (previously Intraject®), enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine and cluster headache. Zogenix submitted a New Drug Application with the U.S. Food and Drug Administration for sumatriptan DosePro in December 2007, and it was accepted for filing by the FDA in March 2008. Zogenix’s second product candidate, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain. This product candidate has completed Phase 2 clinical trials, and the company anticipates initiating the Phase 3 clinical program in the second half of 2008. The company also plans to license the patented DosePro drug delivery system to other companies. For additional information, visit www.zogenix.com.
David Nassif, CFO, 858-436-8583
Source: Zogenix, Inc.